OverviewSuggest Edit

Akebia Therapeutics is a pharmaceutical company, which focuses on treatments for ischemia and the improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The Company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme.
TypePublic
Founded2007
HQCambridge, MA, US
Websiteakebia.com
Employee Ratings4.1
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2018)324(+187%)
Job Openings30
Revenue (FY, 2020)$295.3 M(-11%)
Share Price (May 2021)$3.5(+4%)

Key People/Management at Akebia Therapeutics

John Butler

John Butler

President and Chief Executive Officer
Steven K. Burke

Steven K. Burke

Senior Vice President, Research & Development and Chief Medical Officer
Tamara Dillon

Tamara Dillon

Senior Vice President of Human Resources and Chief People Officer
Michel Dahan

Michel Dahan

Senior Vice President and Chief Operating Officer
Nikki Hadas

Nikki Hadas

Senior Vice President, Chief Legal Officer and Secretary
David Spellman

David Spellman

Senior Vice President and Chief Financial Officer
Show more

Akebia Therapeutics Office Locations

Akebia Therapeutics has offices in Cambridge and Washington
Cambridge, MA, US (HQ)
245 First St #1100
Washington, DC, US
1401 H St NW Suite 900
Show all (2)

Akebia Therapeutics Financials and Metrics

Akebia Therapeutics Revenue

Akebia Therapeutics's revenue was reported to be $295.31 m in FY, 2020
USD

Revenue (FY, 2020)

295.3m

Gross profit (FY, 2020)

(601.0k)

Gross profit margin (FY, 2020), %

(0.2%)

Net income (FY, 2020)

(383.5m)

EBIT (FY, 2020)

(376.4m)

Market capitalization (14-May-2021)

551.7m

Closing stock price (14-May-2021)

3.5

Cash (31-Dec-2020)

228.7m

EV

444.0m
Akebia Therapeutics's current market capitalization is $551.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

207.7m335.0m295.3m

Cost of goods sold

6.3m108.9m295.9m

Gross profit

201.5m226.1m(601.0k)

Gross profit Margin, %

97%67%0%
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

48.8m53.2m72.7m100.8m92.0m88.5m30.7m34.4m

Cost of goods sold

22.2m28.6m29.2m18.6m

Gross profit

50.5m72.2m62.8m69.9m

Gross profit Margin, %

70%72%68%79%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

32.8m49.8m187.3m70.2m104.6m147.4m228.7m

Accounts Receivable

48.0k933.0k34.2m16.7m38.9m26.9m

Prepaid Expenses

6.3m15.7m6.6m14.9m

Inventories

1.5m2.6m2.2m114.2m116.3m61.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

126.3m95.4m49.7m27.9m76.2m66.7m43.4m46.2m65.8m87.3m125.4m89.6m158.2m163.5m162.4m62.7m87.2m122.9m115.4m245.4m169.3m

Accounts Receivable

119.4k114.0k57.0k74.0k48.0k14.0k35.9m132.0k688.0k48.4m28.9m29.7m104.9m39.1m24.5m

Prepaid Expenses

1.5m1.7m1.4m2.3m2.1m1.3m2.5m3.9m3.8m3.2m11.2m4.0m8.1m5.2m6.7m15.6m28.6m7.8m8.7m10.0m9.0m

Inventories

115.2m122.1m116.0m111.9m104.6m88.2m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(37.0m)(60.7m)(135.7m)(76.9m)(143.6m)(279.7m)(383.5m)

Depreciation and Amortization

49.4k96.0k296.0k617.0k2.4m38.6m33.6m

Inventories

(773.0k)(1.0m)428.0k26.0k(29.1m)6.2m

Accounts Payable

4.1m231.0k(274.0k)5.0m13.7m1.4m3.7m
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

Akebia Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Keryx Biopharmaceuticals

Akebia Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Akebia Therapeutics Online and Social Media Presence

Embed Graph

Akebia Therapeutics Company Culture

  • Overall Culture

    A+

    99/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Akebia Therapeutics News and Updates

Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31,...

Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors

CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of LeAnne M. Zumwalt to its Board of Directors, effective February 16, 2021. Ms....

Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™

CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the...

Seth Klarman Axes Akebia Therapeutics Stake From Portfolio

Guru's firm divests of holding in biotech company focusing on kidney disease

Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio?

NEW YORK, Oct. 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, ALRN, RIOT, PLUG, and TBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients

CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first regulatory approval of vadadustat, its oral hypoxia-inducible factor...
Show more

Akebia Therapeutics Blogs

Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones

Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones Content Import Mon, 05/10/2021 - 08:04 Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones May 10, 2021 at 8:00 AM EDT This re…

New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

Program Evaluated the Safety and Efficacy of Vadadustat in Adult Patients with Anemia Due to CKD on Dialysis and Not on Dialysis CAMBRIDGE, Mass. , April 28, 2021 /PRNewswire/ --  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people

Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference Content Import Mon, 04/12/2021 - 08:03 Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference April 12, 2021 at 8:00 AM EDT This release is a backf…

Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis

CAMBRIDGE, Mass. , March 30, 2021 /PRNewswire/ --  Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced that it has submitted a New Drug Application (NDA) to the U.S.

Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

CAMBRIDGE, Mass. , March 25, 2021 /PRNewswire/ --  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation 2021 Spring Clinical

Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan

CAMBRIDGE, Mass. , March 24, 2021 /PRNewswire/ --  Akebia Therapeutics, Inc. (Nasdaq: AKBA),  today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for an additional indication for Riona ® Tablets 250mg
Show more

Akebia Therapeutics Frequently Asked Questions

  • When was Akebia Therapeutics founded?

    Akebia Therapeutics was founded in 2007.

  • Who are Akebia Therapeutics key executives?

    Akebia Therapeutics's key executives are John Butler, Steven K. Burke and Tamara Dillon.

  • How many employees does Akebia Therapeutics have?

    Akebia Therapeutics has 324 employees.

  • What is Akebia Therapeutics revenue?

    Latest Akebia Therapeutics annual revenue is $295.3 m.

  • What is Akebia Therapeutics revenue per employee?

    Latest Akebia Therapeutics revenue per employee is $911.4 k.

  • Who are Akebia Therapeutics competitors?

    Competitors of Akebia Therapeutics include AveXis, Juno Therapeutics and AKESOgen.

  • Where is Akebia Therapeutics headquarters?

    Akebia Therapeutics headquarters is located at 245 First St #1100, Cambridge.

  • Where are Akebia Therapeutics offices?

    Akebia Therapeutics has offices in Cambridge and Washington.

  • How many offices does Akebia Therapeutics have?

    Akebia Therapeutics has 2 offices.